Meng is focused on developing RNA production process for mRNA-based products at Life Edit Therapeutics.
Prior to joining Life Edit, Meng was a mRNA process development scientist at Ultragenyx, and Nitto Denko Avecia where she was responsible for the development of in vitro transcription (IVT) conditions and purification process for mRNA-based therapeutics.
Meng received her PhD in Biochemistry from the Ohio State University, where she studied viral genomic RNA and protein interactions in HIV-1 and HTLV-II.
.svg)
.svg)
To rewrite the future by curing disease, making any edit, anywhere.
To pave the way to faster, safer, gene editing therapeutics that cure disease and improve patient lives.
We’re guided by curiosity, rigor, and integrity. We believe in discovery and unlimited potential. We care about science and the lives of patients.
